Welcome to APIDEL SA

APIDEL SA Untitled Document

APIDEL

            2 drug delivery technologies
               7 partnerships with big pharma/biotech
                  12 drugs in development

Apidel is a privately-owned Swiss company. It was founded in 2011 with a round of seed money by the founders. Since then two private-equity rounds were completed with former executives of the pharmaceutical industry.

Apidel has two proprietary drug delivery systems:

Apid-COR

is a sustained-release liquid injection available in pre-filler syringes. It was successfully tested with small molecules, peptides and proteins over periods of up to 6 months.

Apid-SOL

is an aqueous micelle formulation capable of solubilising poorly-soluble drugs. Apid-SOL is well tolerated and increases tissue penetration following application on the skin or in the eye.

Both inventions are protected by patents. The composition-of-matter patent was issued in the US in 2013.

Our technologies and our business model have been validated by the industry

Since it started operating in June 2011, Apidel has signed seven collaborative research agreements and one license option agreement with international pharmaceutical companies, including top ten companies. We have successfully completed tech transfer to one of our partners in 2013. We started building Product Master Files for our polymers.

Untitled Document

RECENT HIGHLIGHTS

APID-SOL is the subject of in a peer reviewed publication

October, 2014: A paper with the title "Targeted cutaneous delivery of ciclosporin A using micellar nanocarriers and the possible role of inter-cluster regions as molecular transport pathways" has been published in the "Journal of Controlled Release".
The drug delivery system used in the study was based on Apidel’s proprietary Apid-SOL technology. (http://www.ncbi.nlm.nih.gov/pubmed/25278258)

APIDEL amongst the TOP100 startups in Switzerland!

October, 2014: “Each year, "startup.ch" launches the TOP 100 STARTUP AWARD in cooperation with the Handelszeitung. From over 100,000 young companies, the 100 most innovative and promising Swiss startups are picked by top startup experts.”

APIDEL TECHNOLOGY is the subject of in a peer reviewed publication

July, 2014: A recent article published in the journal "Molecular Pharmaceutics" has described a study reporting enhanced delivery of tacrolimus into skin tissue using polymeric micelles as a delivery vehicle.
The drug delivery system used in the study was based on Apidel’s proprietary Apid-SOL technology. (http://www.ncbi.nlm.nih.gov/pubmed/25057896)

APIDEL APPOINTS ALLIANCE MANAGER

On March 1^st, 2014, APIDEL has announced the appointment of Victoria Sarraf as its Alliance Manager. Victoria will be based at Apidel's offices at 29 Quai du Mont Blanc, Geneva. Tel: +41 (0)22 731 2180.

APIDEL RECEIVES GRANT OF US PATENT

On January 17^th, 2014, Apidel received notice from the United States Patent Office that its patent application US 13/778,038 would be granted. Together with the previously granted US 11/912,102, Apidel now has granted US patents protecting both its ApidCor and ApidSol drug delivery polymer compounds. Prosecution of applications in US, Canada, Europe, and Japan continues for the Apidel polymers and other aspects of Apidel's proprietary drug delivery technologies.

APIDEL INCREASES FACILITY SPACE, ADDS NEW EMPLOYEES

On October 21^st, 2013, Apidel has announced an increase to its laboratory and office spaces, located in the Geneva area. The company has established a new headquarters office at Quai du Mont Blanc in Geneva, to add to its existing technical facilities in Plan-les-Ouates, within the life science incubator, Eclosion. In parallel, Apidel has increased its fulltime workforce, adding three positions in R&D and business development to manage Apidel's expanding drug delivery project portfolio.